Dr. Sehgal on Managing CRS and Neurotoxicity From CAR T-Cell Therapy

Video

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.

The management strategies for CRS and neurotoxicity depend on the severity of the syndromes, says Sehgal. With regard to CRS experienced with axicabtagene-ciloleucel (axi-cel; Yescarta), most patients get a fever, which is classified as grade 1. These patients can be managed supportively most of the time—often with Tylenol, fluids, or other antipyretics. If the fever continues, or if it escalates to hypotension or organ dysfunction—particularly pulmonary dysfunction—then an interleukin-6 receptor blocker is often used.

If a patient develops CRS that is refractory to supportive care and tocilizumab (Actemra), many centers, in accordance with real-world data, rely on steroids to combat the toxicity. Tocilizumab does not have a role in the management of neurologic toxicity unless there is concurrent CRS. Therefore, patients who develop more severe neurologic toxicity should be moved swiftly to steroids, concludes Sehgal.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.